 Epizyme Inc NASDAQ: EPZM has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The chromosomal abnormality is responsible for about 15 to 20 of multiple myeloma cases and is associated with poor patient prognosis. 